Glycobond Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Liquidation

Glycobond General Information

Description

Developer of carbohydrate-binding peptides designed to diagnose and monitor liver diseases and cancer. The company's peptides are developed using recombinant technology with defined specificities to detect aberrant and cancer-specific glycosylation, an acute-phase plasma protein produced mainly in the liver, enabling physicians to diagnose primary liver diseases and cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Teknikringen 1F
  • 583 30 Linkoping
  • Sweden
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Diagnostic Equipment
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Teknikringen 1F
  • 583 30 Linkoping
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glycobond Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Bankruptcy: Liquidation 02-Sep-2024 Completed Bankruptcy: Liquidation
6. Later Stage VC 31-Dec-2020 Completed Generating Revenue
5. Grant 15-Dec-2017 Completed Generating Revenue
4. Later Stage VC 11-Apr-2017 Completed Generating Revenue
3. Later Stage VC 08-Nov-2016 Completed Generating Revenue
2. Early Stage VC 08-Apr-2015 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2015 Completed Generating Revenue
To view Glycobond’s complete valuation and funding history, request access »

Glycobond Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Glycobond’s complete cap table history, request access »

Glycobond Patents

Glycobond Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11467162-B2 Diagnostic test for hepatocellular carcinoma Active 09-May-2016
US-20200319189-A1 Diagnostic test for hepatocellular carcinoma Active 09-May-2016
JP-6189499-B1 Novel binding assay Active 09-May-2016
EP-3455634-A2 Novel binding assay Inactive 09-May-2016
JP-2017203762-A Novel binding assay Active 09-May-2016 G01N33/57438
To view Glycobond’s complete patent history, request access »

Glycobond Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glycobond FAQs

  • When was Glycobond founded?

    Glycobond was founded in 2011.

  • Where is Glycobond headquartered?

    Glycobond is headquartered in Linkoping, Sweden.

  • What is the size of Glycobond?

    Glycobond has 3 total employees.

  • What industry is Glycobond in?

    Glycobond’s primary industry is Discovery Tools (Healthcare).

  • Is Glycobond a private or public company?

    Glycobond is a Private company.

  • What is Glycobond’s current revenue?

    The current revenue for Glycobond is .

  • How much funding has Glycobond raised over time?

    Glycobond has raised $167K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »